The ODYSSEY outcome study, including subjects with recent acute coronary syndrome on high dose statin therapy, investigated the effect of 75-150 mg alirocumab given subcutaneously every 2 weeks for 2,8 years in comparison with participants on alirocumab placebo Alirocumab decreased the risk of the primary endpoint coronary death, acute myocardial infarction, hospital admittance because of angina pectoris and ischaemic stroke by 15 percent, decreased the risk of total death by 15 percent and was safe and tolerable during the length of the study.